Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Hepatitis B (HBV) is a blood-borne virus that attacks the liver, causing both acute and chronic disease. It can be transmitted through sexual intercourse, sharing drug injecting equipment or from mother to baby.
More than 250 million people worldwide were living a with a chronic HBV infection in 2015. In the same year, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and primary liver cancer.
Though HBV is fifty times more infectious than HIV, there is a 95 per cent effective vaccine available. Vaccinating a baby in the first 24 hours of life against the virus is potentially lifesaving, yet millions of children in resource-poor countries are still missing out.
In Australia, 226,612 people were living with chronic hepatitis B in 2018. Aboriginal and Torres Strait Islanders people are disproportionately affected and were estimated to make up 6.3 per cent of the total number of cases.
ACCESS: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmitted Infections
Cancer information compared to Hepatitis B information to INcreAse hepatitis B testing in Melbourne’s Chinese community (CHINA-B study)
Healthy Mothers, Healthy Babies
Hepatitis B discrimination and health service access.
Hepatitis B Modelling
Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B.
Identifying the structural enablers to the clinical management of people with hepatitis B in general practice: a qualitative investigation
Improving Hepatitis B Virus screening in general practice in Victoria
Methods for improved sensitivity of lateral flow tests
Modelling for evidence-based national hepatitis B testing plans
Needle and Syringe Program (NSP) Snapshot Study
SuperMIX: The Melbourne Injecting Drug User Cohort Study
The B-VAX Project: Hep B vaccinations for people who inject drugs
The elimination of hepatitis C as a global public health threat
ALT point-of-care diagnostic to detect liver disease
SHARP: Screening for Hepatitis in At-Risk Populations
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
